476198-97-7

Basic information

• Product Name: 5-fluoro-4-methoxy-benzothiophene-2-carboxylic acid
• Synonyms: 5-fluoro-4-methoxy-1-benzothiophene-2-carboxylic acid
• CAS NO: 476198-97-7
• Molecular Formula: C₁₀H₇FO₃S
• Molecular Weight: 226.22
• Mol File: 476198-97-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 420°C at 760 mmHg
• Flash Point: 207.8°C
• Density: 1.471g/cm³
• Vapor Pressure: 8.35E-08mmHg at 25°C
• Refractive Index: 1.649
• CAS DataBase Reference: 5-fluoro-4-methoxy-benzothiophene-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-fluoro-4-methoxy-benzothiophene-2-carboxylic acid(476198-97-7)
• EPA Substance Registry System: 5-fluoro-4-methoxy-benzothiophene-2-carboxylic acid(476198-97-7)

Safety Data

• Hazardous Substances Data: 476198-97-7(Hazardous Substances Data)

Upstream product

• 476198-90-0 (2Z)-3-(3-fluoro-2-methoxyphenyl)-2-mercapto-2-propenoic acid 
• 394-50-3 3-fluorosalicylaldehyde 
• 74266-68-5 fluoro-3 methoxy-2 benzaldehhyde 
• 796087-21-3 5-[1-(3-Fluoro-2-methoxy-phenyl)-meth-(Z)-ylidene]-2-thioxo-thiazolidin-4-one 

Downstream Products

• 476199-22-1 5-fluoro-4-hydroxybenzothiophene 
• 476199-74-3 4-(3-chloro-1-phenyl-propoxy)-5-fluoro-benzo[b]thiophene 
• 476199-45-8 4-(3-chloro-1-phenyl-propoxy)-5-fluoro-benzo[b]thiophene 

Relevant articles and documents

Benzothienyloxy phenylpropanamines, novel dual inhibitors of serotonin and norepinephrine reuptake

A series of benzothienyloxy phenylpropylamines have been prepared and are demonstrated to be inhibitors of both serotonin and norepinephrine reuptake. A series of benzothienyloxy propylamines have been prepared and are demonstrated to be inhibitors of both serotonin and norepinephrine reuptake.

3-ARYLOXY/ THIO-2, 3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPINEPHRINE REUPTAKE

There is provided a compound of formula (I) wherein A is selected from -O- and -S-; X is selected from phenyl optionally substituted with up to 5 substituents each independently selected from halo, C1-C4 alkyl and C1-C4 alkoxy, thienyl optionally substituted with up to 3 substituents each independently selected from halo and C1-C4 alkyl, and C2-C8 alkyl, C2-C8 alkenyl, C3-C8 cycloalkyl and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, -CF3, -CN and -CONH2; Y is selected from phenyl, naphthyl, dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, up to 5 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, nitro, acetyl, -CF3, -SCF3 and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C1-C4 alkyl; Z is selected from OR3 or F, wherein R3 is selected from H, C1-C6 alkyl and phenyl C1-C6 alkyl; R1 and R2 are each independently H or C1-C4 alkyl; and pharmaceutically acceptable salts thereofwith the proviso that when Y is optionally substituted phenyl or optionally substituted 1,3-benzodioxolyl and Z is OR3 and X is optionally substituted phenyl then A is -S-.